Biomarkers of Bone Turnover in Diagnosis and Therapy of Osteoporosis: a Consensus Advice from an Austrian Working Group

Overview

Journal Wien Med Wochenschr

Specialty General Medicine

Date 2012 Aug 15

PMID 22890523

Citations 12

Authors

Christian Bieglmayer

Hans Peter Dimai

Rudolf Wolfgang Gasser

Stefan Kudlacek

Barbara Obermayer-Pietsch

Wolfgang Woloszczuk

Elisabeth Zwettler

Andrea Griesmacher

Affiliations

Soon will be listed here.

Abstract

Aim: Reasonable application of laboratory parameters in prevention, diagnosis, treatment and therapy monitoring of osteoporosis.

Target Groups: Physicians from different specialist disciplines (general medicine, geriatrics, gynaecology, urology, internal medicine-especially endocrinology and metabolism, nephrology, laboratory medicine, rheumatology, nuclear medicine, orthopaedics, paediatrics, rehabilitation and physical medicine, radiology, social medicine, transplantation medicine, accident surgery), moreover social insurances, hospitals and self-help groups.

Background: Evaluation of aetiology of bone disorders, widening of the therapeutic spectrum for diseases of bone and knowledge on biochemical markers of bone turnover. Improvements in judging the success of therapy and in monitoring the compliance of patients. Research perspectives.

Bases: Scientific literature and guidelines, consensus meetings. RÉSUMÉ: Basic and specialized laboratory investigations are important in differentiation between primary and secondary osteoporosis for an adequate therapy. Biochemical markers of bone turnover are an additional aid in evaluation of individual fracture risk. These markers identify responders to bone therapy faster than surveillance of bone mineral density, which helps to improve patient's compliance too. Characteristics, preanalytic precautions and applications are presented for selected markers of bone resorption and formation and for parameters regulating bone metabolism.

Citing Articles

Protocol for preliminary, multicenteric validation of "PoCOsteo device": A point of care tool for proteomic and genomic study of osteoporosis.

Razi F, Ostovar A, Fahimfar N, Amoli M, Fana S, Dimai H Biol Methods Protoc. 2024; 9(1):bpae006.

PMID: 38559752 PMC: 10978377. DOI: 10.1093/biomethods/bpae006.

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study.

Ikeda M, Wakabayashi Y, Okamoto K, Yanagimoto S, Okugawa S, Moriya K AIDS Res Ther. 2021; 18(1):30.

PMID: 34044856 PMC: 8161649. DOI: 10.1186/s12981-021-00354-y.

[Long-term treatment concepts for osteoporosis].

Obermayer-Pietsch B, Fossl I, Dimai H Internist (Berl). 2021; 62(5):474-485.

PMID: 33710362 PMC: 8079292. DOI: 10.1007/s00108-021-00993-3.

Tight control: a new therapeutic strategy in the management of osteoporotic patients.

Halasi A, Kincse G, Varga J, Keri J, Gaal J Osteoporos Int. 2018; 29(12):2677-2683.

PMID: 30167720 DOI: 10.1007/s00198-018-4674-7.

Metabolomic Pathways to Osteoporosis in Middle-Aged Women: A Genome-Metabolome-Wide Mendelian Randomization Study.

Moayyeri A, Cheung C, Tan K, Morris J, Cerani A, Mohney R J Bone Miner Res. 2017; 33(4):643-650.

PMID: 29232479 PMC: 5972819. DOI: 10.1002/jbmr.3358.

References

Maricic M, Adachi J, Sarkar S, Wu W, Wong M, Harper K . Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med. 2002; 162(10):1140-3. DOI: 10.1001/archinte.162.10.1140. View

Black D, Greenspan S, Ensrud K, Palermo L, McGowan J, Lang T . The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349(13):1207-15. DOI: 10.1056/NEJMoa031975. View

Fernandez-Real J, Izquierdo M, Ortega F, Gorostiaga E, Gomez-Ambrosi J, Moreno-Navarrete J . The relationship of serum osteocalcin concentration to insulin secretion, sensitivity, and disposal with hypocaloric diet and resistance training. J Clin Endocrinol Metab. 2008; 94(1):237-45. DOI: 10.1210/jc.2008-0270. View

Cummings S, San Martin J, McClung M, Siris E, Eastell R, Reid I . Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8):756-65. DOI: 10.1056/NEJMoa0809493. View

Takkouche B, Montes-Martinez A, Gill S, Etminan M . Psychotropic medications and the risk of fracture: a meta-analysis. Drug Saf. 2007; 30(2):171-84. DOI: 10.2165/00002018-200730020-00006. View

Bischoff-Ferrari H, Willett W, Wong J, Giovannucci E, Dietrich T, Dawson-Hughes B . Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005; 293(18):2257-64. DOI: 10.1001/jama.293.18.2257. View

Colford J, Sailer D, Langman C . Five osteocalcin assays compared: tracer specificity, fragment interference, and calibration. Clin Chem. 1997; 43(7):1240-1. View

Ravn P, Clemmesen B, Riis B, Christiansen C . The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone. 1996; 19(5):527-33. DOI: 10.1016/s8756-3282(96)00229-3. View

Huber F, Traber L, Roth H, Heckel V, Schmidt-Gayk H . Markers of bone resorption--measurement in serum, plasma or urine?. Clin Lab. 2004; 49(5-6):203-7. View

10.

Tonino R, Meunier P, Emkey R, Menkes C, Wasnich R, Bone H . Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab. 2000; 85(9):3109-15. DOI: 10.1210/jcem.85.9.6777. View

11.

Cauley J, Thompson D, Ensrud K, Scott J, Black D . Risk of mortality following clinical fractures. Osteoporos Int. 2000; 11(7):556-61. DOI: 10.1007/s001980070075. View

12.

Szulc P, Delmas P . Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int. 2008; 19(12):1683-704. DOI: 10.1007/s00198-008-0660-9. View

13.

Woitge H, Friedmann B, Suttner S, Farahmand I, Muller M, Schmidt-Gayk H . Changes in bone turnover induced by aerobic and anaerobic exercise in young males. J Bone Miner Res. 1998; 13(12):1797-804. DOI: 10.1359/jbmr.1998.13.12.1797. View

14.

Chen P, Satterwhite J, Licata A, Lewiecki E, Sipos A, Misurski D . Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005; 20(6):962-70. DOI: 10.1359/JBMR.050105. View

15.

Loke Y, Singh S, Furberg C . Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2008; 180(1):32-9. PMC: 2612065. DOI: 10.1503/cmaj.080486. View

16.

Naylor K, Iqbal P, Fledelius C, Fraser R, Eastell R . The effect of pregnancy on bone density and bone turnover. J Bone Miner Res. 2000; 15(1):129-37. DOI: 10.1359/jbmr.2000.15.1.129. View

17.

Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J . Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344(19):1434-41. DOI: 10.1056/NEJM200105103441904. View

18.

. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

19.

Brown J, Thomson C, Ellis S, Gutcher S, Purohit O, Coleman R . Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer. 2003; 89(11):2031-7. PMC: 2376859. DOI: 10.1038/sj.bjc.6601437. View

20.

Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A . Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem. 1996; 42(6 Pt 1):947-54. View